Structural and functional characterization of a specific antidote for ticagrelor

Blood

Volumn 125, Issue 22, 2015, Pages 3484-3490

  Buchanan, Andrew ^a   Newton, Philip ^a   Pehrsson, Susanne ^b,c,d   Inghardt, Tord ^b   Antonsson, Thomas ^b   Svensson, Peder ^b,c,d   Sjögren, Tove ^b   Öster, Linda ^b   Janefeldt, Annika ^b   Sandinge, Ann Sofie ^b   Keyes, Feenagh ^a   Austin, Mark ^a   Spooner, Jennifer ^a   Gennemark, Peter ^b   Penney, Mark ^a   Howells, Garnet ^c   Vaughan, Tristan ^a   Nylander, Sven ^b  

^a MEDIMMUNE   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA   (United Kingdom)

^d Integrative Research Laboratories   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTIDOTE; MEDI 2452; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; UNCLASSIFIED DRUG; ADENOSINE; ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT;

ACUTE CORONARY SYNDROME; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTINUOUS INFUSION; CRYSTAL STRUCTURE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; TREATMENT RESPONSE; X RAY CRYSTALLOGRAPHY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; HAMSTER; HEMORRHAGE; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PROTEIN ENGINEERING;

ADENOSINE; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ANTIDOTES; CHO CELLS; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MODELS, MOLECULAR; PLATELET AGGREGATION; PROTEIN ENGINEERING;

EID: 84930958754     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-622928     Document Type: Article

References (22)

1. VAN Giezen JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7(9):1556-1565.
2. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
3. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 ACC/AHA guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24): e139-e228.
4. Steg PG, James SK, Atar D, et al; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20):2569-2619.
5. Taylor G, Osinski D, Thevenin A, Devys JM. Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery? J Trauma Acute Care Surg. 2013;74(5): 1367-1369.
6. Pruller F, Drexler C, Archan S, Macher S, Raggam RB, Mahla E. Low platelet reactivity is recovered by transfusion of stored platelets: a healthy volunteer in vivo study. J Thromb Haemost. 2011;9(8):1670-1673.
7. Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med. 2015;372(2):196-197.
8. Dalén M, Ivert T, Lindvall G, van der Linden J. Ticagrelor-associated bleeding in a patient undergoing surgery for acute type A aortic dissection. J Cardiothorac Vasc Anesth. 2013; 27(5):e55-e57.
9. Dolgin E. Antidotes edge closer to reversing effects of new blood thinners. Nat Med. 2013; 19(3):251.
10. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013; 121(18):3554-3562.
11. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446-451.
12. Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22): 2141-2142.
13. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007; 50(19):1852-1856.
14. Husted SE, Storey RF, Bliden K, et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Clin Pharmacokinet. 2012; 51(6):397-409.
15. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38(9):1514-1521.
16. Daramola O, Stevenson J, Dean G, et al. A high-yielding CHO transient system: coexpression of genes encoding EBNA-1 and GS enhances transient protein expression. Biotechnol Prog. 2014; 30(1):132-141.
17. Oprea TI, Nielsen SK, Ursu O, et al. Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing. Mol Inform. 2011;30(2-3):100-111.
18. Springthorpe B, Bailey A, Barton P, et al. From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett. 2007;17(21):6013-6018.
19. Fanning SW, Horn JR. An anti-hapten camelid antibody reveals a cryptic binding site with significant energetic contributions from a nonhypervariable loop. Protein Sci. 2011;20(7): 1196-1207.
20. Zhang K, Zhang J, Gao ZG, et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature. 2014;509(7498): 115-118.
21. Cattaneo M, Schulz R, Nylander S. Adenosinemediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63(23):2503-2509.
22. Sill én H, Cook M, Davis P. Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(23):2315-2322.